Pediatric Obesity and Real-World Use of GLP-1 Receptor Agonists in Adolescents

Early Signals from an Integrated Care Program

A Preventive Pediatrics Perspective on Chronicity, Health Inequities, and Safety

Lea este articulo en español: Version Español

One of the most consequential “diseases” in modern well-child care is not infectious, yet it spreads through environments and inequities: pediatric obesity, a complex chronic condition that increases cardiometabolic risk and shapes physical, mental, and social health. Clinically, it reflects excess adiposity (often operationalized with pediatric BMI percentiles) with potential comorbidities. Epidemiologically, its burden is high and persistent, linked to social determinants, obesogenic environments, structural inequities, and family trajectories. Pathophysiologically, it involves adipose dysfunction, insulin resistance, low-grade inflammation, neurohormonal appetite and satiety dysregulation, and downstream effects on liver health, lipids, and blood pressure. Effective treatment is typically multimodal: intensive family-centered lifestyle intervention, mental health support, comorbidity management, and in selected cases pharmacotherapy and metabolic surgery under appropriate criteria.

Against this background, a very recent Pediatrics (AAP) article describes characteristics of adolescents seen in an integrated weight-management program who were prescribed GLP‑1 receptor agonists between 2023 and 2025 (Characteristics-of-Youth-Treated-With-GLP-1RAs-at).   The point of this kind of study is not to “sell” a medication, but to illuminate how guidelines and clinical reality translate into who receives treatment, what risk profiles are prioritized, and what metabolic markers are being tracked in practice.

My epidemiologic reading is straightforward: when therapeutic innovations enter routine care, they often do so first through pathways with stronger access—integrated programs, specialty referrals, and certain insurance structures—and that can widen gaps unless equity is intentionally built in. A finding that a meaningful proportion of adolescents received GLP‑1RAs within a specific program must be interpreted carefully: it does not automatically represent the general population, but it does foreshadow practice trends.   From a well-child care standpoint, the message is that school-age and adolescent preventive visits must include active, longitudinal screening for obesity and comorbidities (fatty liver disease, dyslipidemia, prediabetes/type 2 diabetes, hypertension, and mental health), plus an honest conversation about options, benefits, risks, adherence, and expectations.

As a pediatrician-epidemiologist, I value three points. First, obesity is not solved in the exam room alone—but the exam room can detect early disease, reduce stigma, and activate networks of care. Second, pharmacotherapy may be appropriate for selected patients, but it demands a safety framework, sustained follow-up, and distributive justice; it should not displace family, school, and community interventions, nor become a “shortcut” that ignores social determinants. Third, real-world data matter most when they push an ethical and epidemiologic question: who gets left behind as treatment advances? In the end, that is the spirit of puericultura—protecting the future while ensuring innovation does not amplify inequality.